Amylin is a pancreatic hormone co-secreted with insulin that plays a role in appetite regulation and metabolism.[3][4] Analogues like Petrelintide mimic these effects, leading to increased satiety (a feeling of fullness), delayed gastric emptying, and restoration of sensitivity to the hormone leptin.[1][4][5] This is a distinct mechanism from. “Petrelintide achieved meaningful weight loss with a well-tolerated dosing approach, which is essential to support long-term and sustained benefits in people living with obesity,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. Petrelintide did not affect GE, in terms of acetaminophen AUC0-1 h, AUC0-4 h and Cmax, after a single dose between 0.7 and 2.4 mg or at steady state with once weekly doses up to 9.0 mg (Figure 1 & 2) Petrelintide (Zealand/Roche) and eloralintide (Eli Lilly) are once-weekly amylin analogs aiming to match GLP-1 weight loss with far less nausea. This guide breaks down their Phase 2 data, how they differ, and where amylin fits in the 2026 obesity pipeline. Introduction and Objective: Native amylin, pramlintide (a short-acting amylin analog) and GLP1 based medications have been shown to delay gastric emptying (GE). We assessed the effect of petrelintide, a long-acting amylin analog in development for weight management, on GE in two clinical trials (NCT05096598, NCT05613387). Petrelintide is a rising star in the treatment of obesity, offering efficacy comparable to current GLP-1 receptor agonists but with superior tolerability. Petrelintide does not impact GE either after SD or at steady state in doses up to 9.0 mg. Absence of delayed GE and favorable tolerability profile observed in the phase 1 trials potentially represent a clinically relevant benefit of petrelintide. Delayed Gastric Emptying: Similar to native amylin, Petrelintide slows the rate at which food leaves the stomach, contributing to prolonged satiety and reduced caloric intake.[8] Petrelintide is an investigational long-acting amylin analog being developed by Zealand Pharma for chronic weight management, currently in late-stage clinical trials and designed for once-weekly subcutaneous administration. The past few years have seen the approval of several medications for weight management, but there is an increasing need for new therapies that target ….